A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
Inclusion Criteria:
Exclusion Criteria:
Rochester, New York 14627, United States
Houston, Texas 77030, United States
Vancouver, British Columbia V6T 2B5, Canada
Halilfax, Nova Scotia B3H 2E1, Canada
Verdun, Quebec H4H 1R3, Canada
San Cugat Del Valles, Barcelona 08195, Spain
London, GT LON, WC1N 3BG, United Kingdom